Question special
Lead Moderator

I would like to start by welcoming our authors and experts to our form discussion re: this months NEJM Perspective Piece, “Mitochondrial Replacement Techniques- Implications for the Clinical Community.” Over the next several days I hope help stimulate a debate regarding this technologies role, implication, application, and cost.
We will start the discussion today by addressing the diseases this technology aims to treat. About one in 200 people is born with a pathogenic mtDNA mutation and one in 5,000-10,000 people develop a symptomatic mitochondrial disease. However, the incidence rates may be higher considering the difficulty of accurate diagnosis and the diversity of clinical presentations.